(MedPage Today) — Medicare advisors promote new ASP model, other ways to rein costs
Uncategorized
Polypoidal choroidal vasculopathy with multiple polyps has poorer response to ranibizumab
Polypoidal choroidal vasculopathy with multiple polyps did not respond as well to intravitreal ranibizumab as polypoidal choroidal vasculopathy with a single polyp, according to a study conducted in Japan.“We propose that the stratification of PCV lesions by polyp number may be valuable to understand the prognosis of this condition,” the study authors said.
Uncategorized
AMA inaugurates Andrew W. Gurman as new president
The AMA has sworn in Andrew W. Gurman, MD, as the 171th president of the organization.According to a press release from the AMA, Gurman will focus on three specific areas during his tenure: Improving physician satisfaction and practice sustainability, …
Increasing Prevalence of Ophthalmic Disorders Driving the Growth of the Global Ophthalmic Lasers Market Through 2020, Says Technavio
LONDON–(BUSINESS WIRE)–$ACL #Healthcare–According to the latest market study released by Technavio, the global ophthalmic lasers market is expected to exceed USD 523 million during the forecast period.
Uncategorized
Global Dry (Atrophic) Macular Degeneration Pipeline Report 2016 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Dry (Atrophic) Macular Degeneration – Pipeline Review, H1 2016” report to their offering. This report provides comprehensive information on the therapeutic development for…
Uncategorized
FDA accepts 510(k) premarket notification filing for Xen treatment system
The FDA has accepted the filing of the 510(k) premarket notification application for the Xen Glaucoma Treatment System, Allergan announced in a press release. The system includes the Xen45, which is a minimally invasive gelatin shunt, and the Xen injec…